Nov 18, 2025
SAN FRANCISCO — November 18, 2025 — Viz.ai, the leader in AI-powered disease detection and care coordination, today announced a strategic partnership with IMVARIA Inc., a health tech company pioneering AI-driven digital biomarker solutions. This collaboration expands Viz.ai’s pulmonary portfolio and introduces new AI capabilities that can assess for interstitial lung findings compatible with interstitial lung disease (ILD).
Through this agreement, Viz.ai will leverage IMVARIA’s FDA-cleared ScreenDx™ technology to enhance its suite of intelligent solutions designed to help clinicians and healthcare organizations identify patients who may benefit from specialized evaluation and therapy. The partnership represents a significant step toward enhancing disease recognition and potential intervention considerations for serious respiratory diseases that are often underrecognized until late in their progression.
“Expanding Viz.ai’s capabilities to address debilitating pulmonary conditions is a critical step forward in our mission to improve outcomes in every corner of the health system,” said Andrew M. Ibrahim, MD, MSc, Chief Clinical Officer at Viz.ai. “Through our collaboration with IMVARIA, we’re bringing together best-in-class AI and care coordination technology with the goal of enabling automated detection of findings in this serious and often underrecognized condition of ILD.”
ILD, including subtypes like idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), affects hundreds of thousands of people in the United States. It is often diagnosed late, sometimes after complications such as pulmonary hypertension associated with ILD (PH-ILD) have already developed. Because early symptoms are often nonspecific and imaging findings are subtle or overlooked, many patients experience diagnostic delays—averaging more than two years—before receiving an accurate diagnosis.1,2 By connecting Viz.ai’s market-leading platform with advanced AI technologies like IMVARIA’s ScreenDx, the company aims to build on its foundation for earlier identification of suspected findings, timely specialist referral, and potentially improved access to emerging therapies.
“Partnering with Viz.ai allows us to bring the benefits of our AI technology to a broader audience of clinicians and patients,” said Joshua Reicher, MD, co-founder and CEO at IMVARIA. “Together, we have the potential to accelerate the discovery and treatment journey for those living with serious pulmonary diseases.”
About Viz.ai
Viz.ai is the leader in AI-powered care coordination and clinical workflow solutions, deployed in over 1,800 hospitals across the U.S. and trusted by most of the top life sciences companies. Its platform uses artificial intelligence to detect diseases earlier, synchronize care teams, and ensure patients get to the right treatment faster. Viz.ai was the first company awarded CMS reimbursement for AI and ranked the #1 Healthcare AI Platform by hospitals and health systems in the Black Book Research survey, setting the standard for innovation in healthcare. For more information visit Viz.ai.
About IMVARIA Inc.
IMVARIA is a health tech company pioneering AI-driven solutions that empower clinicians to make accurate diagnoses and prognoses at earlier stages of disease. Founded in 2019 by physician-engineers from Google and Stanford University, the company operates its AI Platform with automated, machine-learning algorithm technology to transform clinical decision-making into data science. IMVARIA is based in Berkeley, CA. For more information, go to www.imvaria.com.
Media Contacts
Carolyn Jones
carolyn.jones@viz.ai
Daniel Yunger / Daniel Hoadley
daniel.yunger@kekstcnc.com / daniel.hoadley@kekstcnc.com
References
1. Cosgrove GP, Bianchi P, Danese S, Lederer DJ. Barriers to timely diagnosis of interstitial lung disease in the real world: the INTENSITY survey. BMC Pulm Med. 2018 Jan 17;18(1):9. doi: 10.1186/s12890-017-0560-x. PMID: 29343236; PMCID: PMC5773175.
2. Herberts, M.B., Teague, T.T., Thao, V. et al. Idiopathic pulmonary fibrosis in the United States: time to diagnosis and treatment. BMC Pulm Med 23, 281 (2023). https://doi.org/10.1186/s12890-023-02565-7